ClinicalTrials.gg

Program

EDP167

A development code. Also written as “EDP167 100mg”, “EDP167 200mg” and “EDP167 300mg”.

Its studies are mostly in Dyslipidemias · Homozygous Familial Hypercholesterolemia, led by Eddingpharm (Zhuhai).

Furthest: phase 2, since Mar 19, 20263 company-led studies, 2 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eddingpharm (Zhuhai)32 open or runningphase 2since Mar 19, 2026Feb 2, 2026Nov 2027phase 2 · NCT07799129

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 2, 2026First study: phase 1 study in DyslipidemiasFirst studyNCT07412080 · 40 enrolled · China
  2. Mar 19, 2026Phase 2 study in Homozygous Familial HypercholesterolemiaPhase 2 reachedNCT07489209 · 20 planned · China
  3. Aug 27, 2026Phase 2 study in DyslipidemiasNCT07799129 · 144 planned · China

Ahead

  1. Nov 2027Primary completion: phase 2 study in DyslipidemiasNCT07799129

TargetBeta

ANGPTL3 →read by rule
“EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions.”study text, by rule · the study

Other programs on ANGPTL3

ProgramCompanyFurthest phaseStudies
SHR-1918Jiangsu HengRui Medicinephase 38
VSA003rulevisirna-therapeutics-hk-limitedphase 32

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07799129Dyslipidemias · China2Not yet recruitingNov 2027144
NCT07489209Homozygous Familial Hypercholesterolemia · China2RecruitingOct 4, 202620
NCT07412080Dyslipidemias · China1CompletedDec 12, 202540

How it is read

Names in the registry

  • “EDP167”, 2 entries
  • “EDP167 100mg”, 1 entry
  • “EDP167 200mg”, 1 entry
  • “EDP167 300mg”, 1 entry

Codes read as this program: EDP167.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.